CME Options – CME-certified programs developed independently by CCO's educational partners
Virtual Presentations
Historical perspective on the treatment challenges for low-grade NHL
CME Program Director:
Stephanie A. Gregory, MD
Faculty:
Fernando Cabanillas, MD
|
|
 Learning Objectives
Upon completion of this activity, participants should be able to:
- Trace the history of lymphoma from the time of Thomas Hodgkin through the subsequent differentiations and classifications of the various types of lymphoma
- Discuss some of the advances achieved in the management of indolent lymphoma during the last decade
- Explain why a new paradigm for NHL might be appropriate today
|
Current therapeutic approaches to patients with newly diagnosed low-grade NHL
CME Program Director:
Stephanie A. Gregory, MD
Faculty:
Stephanie A. Gregory, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the risks and benefits of initial therapy for advanced stage low-grade follicular NHL
- Enumerate factors to consider when choosing initial therapy for patients with low-grade follicular NHL and describe how the Follicular Lymphoma International Prognostic Index (FLIPI) and NCCN Practice Guidelines impact the choice
- Examine the patterns of care of follicular lymphoma patients in the United States
|
Current options for the treatment of patients with relapsed/refractory and transformed indolent NHL
CME Program Director:
Stephanie A. Gregory, MD
Faculty:
Thomas E. Witzig, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss issues in choosing the next therapy for rituximab-refractory or relapsed indolent lymphoma patients
- Identify what should be included in the routine evaluation of relapsed lymphomas
- Outline salvage treatment options for previously treated relapsed follicular NHL patients
|
New agents in development for NHL
CME Program Director:
Stephanie A. Gregory, MD
Faculty:
John P. Leonard, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify and describe new agents in development for treatment of NHL
- Describe the mechanism of action of rituximab and ways to improve upon this agent
- Assess the possible uses of radioimmunotherapy in NHL and the monoclonal antibodies already available or in development for NHL
|
German experience with bendamustine for treating refractory/relapsed indolent B-cell and mantle cell NHL
CME Program Director:
Stephanie A. Gregory, MD
Faculty:
Mathias Rummel, MD, PhD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the agent bendamustine and describe its history and uses in Germany
- Summarize some of the clinical studies conducted in Germany of bendamustine in combination with other chemotherapy in advanced low-grade NHL
- Discuss some of the synergistic effects of combining bendamustine with rituximab
|
Rituximab resistance and the US clinical experience with Bendamustine
CME Program Director:
Stephanie A. Gregory, MD
Faculty:
Jonathan W. Friedberg, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain some of the mechanisms of resistance to rituximab
- Discuss the single-agent use of bendamustine in the United States in relapsed indolent or transformed NHL
- Compare the US experience with bendamustine to that of 90[Y]- ibritumomab and 131[I]-tositumomab
|
Copyright © 2007 Rush University Medical Center. All rights reserved.
About CME Options
CME Options programs are educational programs published on the CCO Web site, developed by third-party organizations, not by CCO, and certified by accredited providers. Disclosure information for faculty involved in the development of a CME Options program is obtained from the faculty by the accredited provider and provided to CCO for publication. CCO has received a fee for publishing these activities on the CCO Web site. Please direct questions or comments to memberservices@clinicaloptions.com.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Sponsored for CME credit by Rush University Medical Center.
Contact Info
Supported by an unrestricted educational grant from:
Educational grants support only the CME-certified components of this program.
|
|